ScholarIQanswers from OpenAlex & ORCID
Thomas E. Witzig
ResearcherPublications, citations & collaboration network
Thomas E. Witzig is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Thomas E. Witzig have?
ScholarIQindexed works
Thomas E. Witzig has 1,274 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Thomas E. Witzig have?
ScholarIQcitation count
Thomas E. Witzig has 62,755 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Thomas E. Witzig?
ScholarIQh-index
Thomas E. Witzig has an h-index of 131 in OpenAlex.
What is the i10-index of Thomas E. Witzig?
ScholarIQi10-index
Thomas E. Witzig has an i10-index of 549 in OpenAlex.
What is the ORCID of Thomas E. Witzig?
ScholarIQorcid
The ORCID for Thomas E. Witzig is on the source record.
What is the OpenAlex record for Thomas E. Witzig?
ScholarIQopenalex
The OpenAlex for Thomas E. Witzig is on the source record.
What are the most-cited papers on Thomas E. Witzig?
ScholarIQmost cited works
International Consensus Guidance Statement on the Management and Treatment of IgG4‐Related Disease
Arezou Khosroshahi, Zachary S. Wallace, Jayne Littlejohn Crowe, Takashi Akamizu, Atsushi Azumi, Mollie N. Carruthers, Suresh T. Chari, Emanuel Della‐Torre, Luca Frulloni, Hiroshi Gotô, Phil A. Hart, Terumi Kamisawa, Shigeyuki Kawa, Mitsuhiro Kawano, M. H. Kim, Yuzo Kodama, Kensuke Kubota, Markus M. Lerch, Matthias Löhr, Yasufumi Masaki, Shoko Matsui, Tsuneyo Mimori, Shôji Nakamura, Takahiro Nakazawa, Hitomi Ohara, Kazuichi Okazaki, Jay H. Ryu, Takako Saeki, N. Schleinitz, Akira Shimatsu, Tooru Shimosegawa, Hiroki Takahashi, Masayuki Takahira, Atsushi Tanaka, Mark Topazian, Hisanori Umehara, George Webster, Thomas E. Witzig, Motohisa Yamamoto, Wen Zhang, T. Chiba, John H. Stone
Rituximab for IgG4-related disease: a prospective, open-label trial
Mollie N. Carruthers, Mark Topazian, Arezou Khosroshahi, Thomas E. Witzig, Zachary S. Wallace, Philip Hart, Vikram Deshpande, Thomas C. Smyrk, Suresh T. Chari, John H. Stone
Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience
Phil A. Hart, Mark Topazian, Thomas E. Witzig, Jonathan E. Clain, Ferga C. Gleeson, Robin Klebig, Michael J. Levy, Randall K. Pearson, Bret T. Petersen, Thomas C. Smyrk, Aravind Sugumar, Naoki Takahashi, Santhi Swaroop Vege, Suresh T. Chari
Safety of Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed Low-Grade, Follicular, or Transformed Non-Hodgkin’s Lymphoma
Thomas E. Witzig, Christine A. White, Leo I. Gordon, Gregory A. Wiseman, Christos Emmanouilides, James L. Murray, John Lister, Pratik S. Multani
Phase III, Randomized, Double-Blind Study of Epoetin Alfa Compared With Placebo in Anemic Patients Receiving Chemotherapy
Thomas E. Witzig, Peter T. Silberstein, Charles L. Loprinzi, Jeff A. Sloan, Paul J. Novotny, James A. Mailliard, Kendrith M. Rowland, Steven R. Alberts, James E. Krook, Ralph Levitt, Roscoe F. Morton